Key result
Empagliflozin significantly reduced estimated plasma volume by 5.60% and estimated extracellular volume by 144.4 mL compared to placebo at 24 weeks in patients with type 2 diabetes and cardiovascular disease.
Why the study?
SGLT2 inhibitors promote diuresis and reduce excess fluid volume to improve cardiovascular outcomes, but the specific effect of empagliflozin on estimated fluid volumes in patients with type 2 diabetes and CVD required evaluation.
Does empagliflozin reduce estimated fluid volumes in adults with type 2 diabetes and established cardiovascular disease?
Comparison
Empagliflozin (10 mg once daily) vs placebo
Design
Post-hoc analysis of a multicenter, placebo-controlled, double-blind randomized controlled trial
Follow-up
24 weeks
Authors
Loading...
Provides mechanistic support for empagliflozin's early CV benefits; extends SGLT2 inhibitor trial data on volume effects in T2D with CVD.
RCT (n=105)
Double-blind
randomized
Yes
Does empagliflozin reduce estimated fluid volumes in adults with type 2 diabetes and established cardiovascular disease?
Mean Difference: -5.6 (95% CI -9.87–-1.32)
Absolute Event Rate: -6.66% vs -1.13%
Empagliflozin significantly reduces estimated plasma and extracellular volumes in patients with type 2 diabetes and cardiovascular disease, providing mechanistic insight into its early cardiovascular benefits.
Tanaka et al. (2021) conducted an RCT in Type 2 diabetes and cardiovascular disease (n=105). Empagliflozin vs. Placebo was evaluated on Percentage change in estimated plasma volume (ePV) from baseline to week 24 (MD -5.60%, 95% CI -9.87 to -1.32). Empagliflozin significantly reduced estimated plasma volume by 5.60% and estimated extracellular volume by 144.4 mL compared to placebo at 24 weeks in patients with type 2 diabetes and cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: